KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 144 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $291,143 | +74.6% | 192,810 | 0.0% | 0.00% | – |
Q4 2023 | $166,781 | -35.4% | 192,810 | 0.0% | 0.00% | – |
Q3 2023 | $258,365 | -38.4% | 192,810 | -17.8% | 0.00% | – |
Q2 2023 | $419,630 | -39.3% | 234,430 | +31.8% | 0.00% | – |
Q1 2023 | $691,759 | +28.7% | 177,830 | +12.5% | 0.00% | – |
Q4 2022 | $537,302 | -28.7% | 158,030 | +14.4% | 0.00% | – |
Q3 2022 | $754,000 | +41.7% | 138,130 | +17.0% | 0.00% | – |
Q2 2022 | $532,000 | -37.8% | 118,030 | +1.7% | 0.00% | – |
Q1 2022 | $855,000 | +14.8% | 116,030 | +0.2% | 0.00% | – |
Q4 2021 | $745,000 | +10.5% | 115,830 | 0.0% | 0.00% | – |
Q3 2021 | $674,000 | -43.6% | 115,830 | 0.0% | 0.00% | – |
Q2 2021 | $1,195,000 | -12.5% | 115,830 | -10.7% | 0.00% | -100.0% |
Q1 2021 | $1,365,000 | -32.0% | 129,730 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $2,008,000 | +6.0% | 129,730 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $1,894,000 | -24.1% | 129,730 | -1.5% | 0.00% | 0.0% |
Q2 2020 | $2,495,000 | +44.9% | 131,730 | +47.0% | 0.00% | 0.0% |
Q1 2020 | $1,722,000 | +0.2% | 89,630 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $1,718,000 | +101.9% | 89,630 | +1.4% | 0.00% | 0.0% |
Q3 2019 | $851,000 | +19.2% | 88,430 | -25.8% | 0.00% | – |
Q2 2019 | $714,000 | +35.0% | 119,130 | +31.6% | 0.00% | – |
Q1 2019 | $529,000 | -12.0% | 90,530 | +41.2% | 0.00% | – |
Q4 2018 | $601,000 | -43.0% | 64,130 | +3.6% | 0.00% | -100.0% |
Q3 2018 | $1,055,000 | +0.3% | 61,930 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $1,052,000 | +7.9% | 61,930 | -14.7% | 0.00% | 0.0% |
Q1 2018 | $975,000 | -14.2% | 72,630 | -38.7% | 0.00% | 0.0% |
Q4 2017 | $1,137,000 | +138.4% | 118,430 | +172.7% | 0.00% | – |
Q3 2017 | $477,000 | +21.4% | 43,430 | 0.0% | 0.00% | – |
Q2 2017 | $393,000 | -7.1% | 43,430 | +31.9% | 0.00% | – |
Q1 2017 | $423,000 | +29.0% | 32,930 | -5.7% | 0.00% | – |
Q4 2016 | $328,000 | -3.5% | 34,930 | 0.0% | 0.00% | – |
Q3 2016 | $340,000 | +45.3% | 34,930 | 0.0% | 0.00% | – |
Q2 2016 | $234,000 | -6.8% | 34,930 | +24.2% | 0.00% | – |
Q1 2016 | $251,000 | -41.2% | 28,130 | -12.7% | 0.00% | – |
Q4 2015 | $427,000 | +9.5% | 32,230 | -13.0% | 0.00% | – |
Q3 2015 | $390,000 | -97.5% | 37,027 | -93.7% | 0.00% | -100.0% |
Q2 2015 | $15,879,000 | +26.8% | 583,570 | +42.6% | 0.01% | +30.0% |
Q1 2015 | $12,527,000 | -20.1% | 409,251 | -2.3% | 0.01% | -23.1% |
Q4 2014 | $15,671,000 | -5.0% | 418,680 | -11.3% | 0.01% | -7.1% |
Q3 2014 | $16,497,000 | -14.1% | 472,146 | +14.5% | 0.01% | -12.5% |
Q2 2014 | $19,201,000 | +39.2% | 412,479 | -7.6% | 0.02% | +33.3% |
Q1 2014 | $13,790,000 | +32.4% | 446,415 | -1.8% | 0.01% | +33.3% |
Q4 2013 | $10,415,000 | – | 454,423 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |